- Home
- BKYI vs QNRX Comparison
BKYI vs QNRX Comparison
Compare BKYI & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- QNRX
- Stock Information
- Founded
- BKYI 1993
- QNRX 2018
- Country
- BKYI United States
- QNRX United States
- Employees
- BKYI N/A
- QNRX N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- QNRX Medical/Dental Instruments
- Sector
- BKYI Technology
- QNRX Health Care
- Exchange
- BKYI Nasdaq
- QNRX Nasdaq
- Market Cap
- BKYI 5.3M
- QNRX 4.8M
- IPO Year
- BKYI 1997
- QNRX N/A
- Fundamental
- Price
- BKYI $0.94
- QNRX $12.98
- Analyst Decision
- BKYI
- QNRX
- Analyst Count
- BKYI 0
- QNRX 0
- Target Price
- BKYI N/A
- QNRX N/A
- AVG Volume (30 Days)
- BKYI 13.7M
- QNRX 835.8K
- Earning Date
- BKYI 11-13-2025
- QNRX 11-07-2025
- Dividend Yield
- BKYI N/A
- QNRX N/A
- EPS Growth
- BKYI N/A
- QNRX N/A
- EPS
- BKYI N/A
- QNRX N/A
- Revenue
- BKYI $6,911,148.00
- QNRX N/A
- Revenue This Year
- BKYI $7.45
- QNRX N/A
- Revenue Next Year
- BKYI $23.29
- QNRX N/A
- P/E Ratio
- BKYI N/A
- QNRX N/A
- Revenue Growth
- BKYI N/A
- QNRX N/A
- 52 Week Low
- BKYI $0.62
- QNRX $5.01
- 52 Week High
- BKYI $3.68
- QNRX $48.30
- Technical
- Relative Strength Index (RSI)
- BKYI 64.67
- QNRX 54.05
- Support Level
- BKYI $0.73
- QNRX $12.55
- Resistance Level
- BKYI $1.97
- QNRX $17.84
- Average True Range (ATR)
- BKYI 0.12
- QNRX 4.54
- MACD
- BKYI 0.02
- QNRX -0.20
- Stochastic Oscillator
- BKYI 18.89
- QNRX 15.11
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.